Pittsburgh -Topical tacrolimus ointment 0.1 percent (Protopic) may be a viable addition to the current therapeutic armamentarium for early-stage cutaneous T-cell lymphoma (CTCL), Larisa Geskin, M.D., said.
Related Content:
